<DOC>
	<DOCNO>NCT02289222</DOCNO>
	<brief_summary>This open label trial Anti PD1/MD-3475 , Pomalidomide dexamethasone . The study use standard ( FDA approve ) dos pomalidomide dexamethasone . The experimental drug Anti PD-1 ( MK 3475 ) give day 1 14 .</brief_summary>
	<brief_title>1454GCC : Anti-PD-1 ( MK-3475 ) IMiD ( Pomalidomide ) Combination Immunotherapy Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>This phase I/II study focus patient relapsed refractory multiple myeloma . MK-3475 give intravenous infusion every 2 week . Treatment administer outpatient basis .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Confirmed diagnosis relapse and/or refractory MM accord International Myeloma Working Group guideline ( 2003 ) 2 . Received two line prior therapy include IMiD ( lenalidomide thalidomide ) proteasome inhibitor ( bortezomib and/or carfilzomib ) ( use either separately combination ) . ( ) . Prior pomalidomide therapy permit , provide patient achieve least partial remission progress 3 month stop therapy . 3 . Measureable disease define protocol ( assess within 28 day prior registration ) . 4 . Be willing able provide write informed consent/assent trial . 5 . Be 18 year age day sign informed consent . 6 . Have performance status 2 ECOG Performance Scale . 7 . Demonstrate adequate organ function define protocol . 8 . Female subject childbearing potential negative serum pregnancy within 72 hour prior receive first dose study drug . 9 . Male subject agree use adequate method contraception . 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency ( HIV ) receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 4 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . ( Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . ) 5 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 6 . Has know active central nervous system disease and/or carcinomatous meningitis . 7 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . 8 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 9 . Has active infection require systemic therapy . 10 . Has history current evidence condition , therapy , lab abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 11 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 12 . Pregnant breastfeeding , expect conceive father child study participation . 13 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody per protocol . 14. known active Hepatitis B Hepatitis C. 15 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) 16 . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>MK-3475 &amp; Pomalidomide</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>